This inventor holds 1 USPTO granted patent. Top assignee: Nektar Therapeutics. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: Alexev Kabalnov: Innovator in Particulate Delivery Systems
Introduction
Alexev Kabalnov is a notable inventor based in Corvallis, OR (US). He has made significant contributions to the field of particulate delivery systems, particularly in the administration of bioactive agents. His innovative work has the potential to enhance therapeutic delivery methods.
Latest Patents
Kabalnov holds a patent for "Particulate delivery systems and methods of use." This invention provides compositions and methods for administering particulates that comprise at least one bioactive agent, which may include an immunoactive agent. The invention facilitates both topical and systemic delivery of the bioactive agent through various tracts, such as respiratory, gastrointestinal, or urogenital. The particulates can be in the form of dry powders or combined with a non-aqueous suspension medium to create stabilized dispersions. The disclosed compositions are designed for use with inhalation devices, including metered dose inhalers, dry powder inhalers, atomizers, or nebulizers, ensuring targeted delivery to mucosal surfaces.
Career Highlights
Kabalnov is associated with Nektar Therapeutics, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving drug delivery systems, which can significantly impact patient care and treatment outcomes.
Collaborations
Kabalnov has collaborated with notable colleagues, including Adrian I Bot and Thomas E Tarara. These partnerships have contributed to the development and refinement of his innovative technologies.
Conclusion
Alexev Kabalnov's contributions to particulate delivery systems exemplify the intersection of innovation and healthcare. His patent and ongoing work at Nektar Therapeutics highlight the importance of advancing drug delivery methods for improved therapeutic efficacy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
